CRISPR Therapy Poised for First FDA Approval of Gene Editing Inside the Body
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Intellia Therapeutics says lonvoguran ziclumeran remains effective four years after treatment. The therapy uses CRISPR-Cas9 inside the body to disable the liver gene producing prekallikrein, aiming to prevent painful, potentially dangerous swelling caused by a genetic disorder.
Continue in the app — vote & join in ➔Source: Nature News · via ahirlevel.hu